Completed PHASE1 INTERVENTIONAL 1-arm NCT01719614

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

A Phase I, Open-Label Study in Healthy Subjects to Explore the Potential for a Pharmacokinetic Interaction Between Steady-State Rilpivirine and a Single Dose Of Metformin

Sponsor: Janssen R&D Ireland

Conditions Healthy Participants

Interventions Metformin Rilpivirine

Updated 6 times since 2017 Last updated: Mar 5, 2014 Started: Oct 31, 2012 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01719614, this PHASE1 trial focuses on Healthy Participants and remains completed. Sponsored by Janssen R&D Ireland, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen R&D Ireland

Data source: Janssen R&D Ireland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States